GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Magnasense AB (FRA:52Q) » Definitions » ROIC %

Magnasense AB (FRA:52Q) ROIC % : -150.48% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Magnasense AB ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Magnasense AB's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2024 was -150.48%.

As of today (2025-03-27), Magnasense AB's WACC % is 27.69%. Magnasense AB's ROIC % is -86.63% (calculated using TTM income statement data). Magnasense AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Magnasense AB ROIC % Historical Data

The historical data trend for Magnasense AB's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magnasense AB ROIC % Chart

Magnasense AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROIC %
Get a 7-Day Free Trial -62.20 -40.93 -39.76 -104.58 -97.22

Magnasense AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.91 -68.62 -44.60 -69.09 -150.48

Competitive Comparison of Magnasense AB's ROIC %

For the Medical Devices subindustry, Magnasense AB's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magnasense AB's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Magnasense AB's ROIC % distribution charts can be found below:

* The bar in red indicates where Magnasense AB's ROIC % falls into.


;
;

Magnasense AB ROIC % Calculation

Magnasense AB's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROIC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=-4.075 * ( 1 - 3.66% )/( (3.898 + 4.178)/ 2 )
=-3.925855/4.038
=-97.22 %

where

Magnasense AB's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2024 is calculated as:

ROIC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-7.304 * ( 1 - 1.54% )/( (5.38 + 4.178)/ 2 )
=-7.1915184/4.779
=-150.48 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Magnasense AB  (FRA:52Q) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Magnasense AB's WACC % is 27.69%. Magnasense AB's ROIC % is -86.63% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Magnasense AB ROIC % Related Terms

Thank you for viewing the detailed overview of Magnasense AB's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Magnasense AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
AegirBio AB is a Swedish diagnostic company, specializes in developing a home testing platform for oral health, therapeutic drug monitoring and infectious diseases. The current product line up includes the Veritope technology, featuring intact natalizumab in MS, along with the MagniaReader designed for both research and veterinary applications.

Magnasense AB Headlines

No Headlines